Drugs / LY2940094
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01404091 | Jul → Nov 2011 | depressive disorder | BlackThorn Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01263236 | Dec 2010 → Sep 2011 | major depressive disorder | BlackThorn Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT06786637 | Jun 2025 → Jan 2026 | anxiety, major depressive disorder | Mclean Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT03608371 | Aug 2018 → Apr 2019 | Parkinson disease, movement disorder | BlackThorn Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03193398 | Jun 2017 → Nov 2018 | major depressive disorder | BlackThorn Therapeutics, Inc. | Completed | Missed primary |
| Phase 2 | NCT01798303 | Jul 2013 → Jun 2014 | alcohol dependence | BlackThorn Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01724112 | Nov 2012 → Mar 2014 | major depressive disorder | BlackThorn Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY-2940094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06786637 ↗ |
| Known as | BTRX-246040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03193398 ↗ |
| Known as | J3.309.394B | ChEMBL registry synonym — accepted as the source's own label CHEMBL3304244 ↗ |
| Action | Inhibit | “Nociceptin receptor antagonist” CHEMBL3304244 ↗ |
| Modality | Small molecule | — CHEMBL3304244 ↗ |
| Route | Oral | “Administered orally” NCT01263236 ↗ |
| Target | OPRL1 | “Nociceptin receptor antagonist” CHEMBL3304244 ↗ |